
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8701586/publications.pdf Version: 2024-02-01



ם מעון דו א

#	Article	IF	CITATIONS
1	Children living with HIV in Europe: do migrants have worse treatment outcomes?. HIV Medicine, 2022, 23, 186-196.	1.0	2
2	Arterial Stiffness in a Cohort of Young People Living With Perinatal HIV and HIV Negative Young People in England. Frontiers in Cardiovascular Medicine, 2022, 9, 821568.	1.1	4
3	Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis. Journal of the International AIDS Society, 2022, 25, e25871.	1.2	8
4	Labour pains: eliminating HCV in women and children. The Lancet Gastroenterology and Hepatology, 2021, 6, 150-151.	3.7	2
5	Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Public Health, The, 2021, 6, e309-e323.	4.7	99
6	Mortality and AIDSâ€defining events among young people following transition from paediatric to adult HIV care in the UK. HIV Medicine, 2021, 22, 631-640.	1.0	9
7	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. Clinical Infectious Diseases, 2021, 73, 50-59.	2.9	18
8	Characterizing the doubleâ€sided cascade of care for adolescents living with HIV transitioning to adulthood across Southern Africa. Journal of the International AIDS Society, 2020, 23, e25447.	1.2	13
9	Outcomes of secondâ€ŀine antiretroviral therapy among children living with HIV: a global cohort analysis. Journal of the International AIDS Society, 2020, 23, e25477.	1.2	5
10	Factors Associated With Nonadherence to Antiretroviral Therapy Among Young People Living With Perinatally Acquired HIV in England. Journal of the Association of Nurses in AIDS Care, 2020, 31, 574-586.	0.4	3
11	The cascade of care for children and adolescents with <scp>HIV</scp> in the <scp>UK</scp> and Ireland, 2010 to 2016. Journal of the International AIDS Society, 2019, 22, e25379.	1.2	6
12	Review article: directâ€acting antivirals for the treatment of HCV during pregnancy and lactation ― implications for maternal dosing, foetal exposure, and safety for mother and child. Alimentary Pharmacology and Therapeutics, 2019, 50, 738-750.	1.9	35
13	Self-harm in young people with perinatal HIV and HIV negative young people in England: cross sectional analysis. BMC Public Health, 2019, 19, 1165.	1.2	5
14	CD4 recovery following antiretroviral treatment interruptions in children and adolescents with HIV infection in Europe and Thailand. HIV Medicine, 2019, 20, 456-472.	1.0	3
15	Severe haematologic toxicity is rare in high risk HIVâ€exposed infants receiving combination neonatal prophylaxis. HIV Medicine, 2019, 20, 291-307.	1.0	3
16	Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study. Clinical Infectious Diseases, 2019, 70, 404-415.	2.9	8
17	Reactivity of Routine HIV Antibody Tests in Children With Perinatally Acquired HIV-1 in England: Cross-sectional Analysis. Pediatric Infectious Disease Journal, 2019, 38, 146-148.	1.1	1
18	Young people in HIV care in Ukraine: a national survey on characteristics and service provision. F1000Research, 2019, 8, 323.	0.8	5

#	Article	IF	CITATIONS
19	Young people in HIV care in Ukraine: a national survey on characteristics and service provision. F1000Research, 2019, 8, 323.	0.8	5
20	Anxiety and depression symptoms in young people with perinatally acquired HIV and HIV affected young people in England. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1040-1049.	0.6	21
21	Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand. Clinical Infectious Diseases, 2018, 66, 594-603.	2.9	12
22	Adolescent transition among young people with perinatal HIV in high-income and low-income settings. Current Opinion in HIV and AIDS, 2018, 13, 236-248.	1.5	26
23	Using Observational Data to Inform HIV Policy Change for Children and Youth. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, S22-S26.	0.9	7
24	Sexual health of young people with perinatal HIV and HIV negative young people in England. PLoS ONE, 2018, 13, e0205597.	1.1	15
25	Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland. PLoS ONE, 2018, 13, e0194132.	1.1	3
26	The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis. PLoS Medicine, 2018, 15, e1002514.	3.9	98
27	Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study. PLoS Medicine, 2018, 15, e1002491.	3.9	29
28	Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe. International Journal of Epidemiology, 2017, 46, dyw097.	0.9	30
29	Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand. European Journal of Clinical Pharmacology, 2017, 73, 463-468.	0.8	7
30	Clinical Status of Adolescents with Perinatal HIV at Transfer to Adult Care in the UK/Ireland. Clinical Infectious Diseases, 2017, 64, 1105-1112.	2.9	35
31	Tracking the transition of adolescents into adult HIV care: a global assessment. Journal of the International AIDS Society, 2017, 20, 21878.	1.2	14
32	Does community support help children take their ART?. The Lancet Child and Adolescent Health, 2017, 1, 160-161.	2.7	1
33	Who Gets Severe Gynecomastia Among HIV-infected Children in the United Kingdom and Ireland?. Pediatric Infectious Disease Journal, 2017, 36, 307-310.	1.1	4
34	Higher rates of tripleâ€class virological failure in perinatally <scp>HIV</scp> â€infected teenagers compared with heterosexually infected young adults in Europe. HIV Medicine, 2017, 18, 171-180.	1.0	45
35	Growing up with perinatal HIV: changes in clinical outcomes before and after transfer to adult care in the UK. Journal of the International AIDS Society, 2017, 20, 21577.	1.2	36
36	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2869-2878.	1.3	17

#	Article	IF	CITATIONS
37	Safety of Darunavir and Atazanavir in HIV-Infected Children in Europe and Thailand. Antiviral Therapy, 2016, 21, 353-358.	0.6	6
38	Tuberculosis in HIV-infected children in Europe, Thailand and Brazil: paediatric TB-HIV EuroCoord study. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1448-1456.	0.6	3
39	Episodic medication adherence in adolescents and young adults with perinatally acquired HIV: a within-participants approach. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 68-75.	0.6	19
40	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	2.9	20
41	Cognitive Function in Young Persons With and Without Perinatal HIV in the AALPHI Cohort in England: Role of Non–HIV-Related Factors. Clinical Infectious Diseases, 2016, 63, 1380-1387.	2.9	29
42	Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children. Antiviral Therapy, 2016, 21, 579-585.	0.6	32
43	Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project. BMC Infectious Diseases, 2016, 16, 654.	1.3	7
44	Interventions to improve treatment, retention and survival outcomes for adolescents with perinatal HIV-1 transitioning to adult care. Current Opinion in HIV and AIDS, 2016, 11, 477-486.	1.5	55
45	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	1.3	4
46	Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort study. Lancet HIV,the, 2015, 2, e530-e539.	2.1	16
47	Outcomes after viral load rebound on first-line antiretroviral treatment in children with HIV in the UK and Ireland: an observational cohort study. Lancet HIV,the, 2015, 2, e151-e158.	2.1	12
48	Incidence of Pneumococcal and Varicella Disease in HIV-infected Children and Adolescents in the United Kingdom and Ireland, 1996–2011. Pediatric Infectious Disease Journal, 2015, 34, 149-154.	1.1	13
49	Post-licensing safety of fosamprenavir in HIV-infected children in Europe. Pharmacoepidemiology and Drug Safety, 2014, 23, 321-325.	0.9	5
50	Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland. Aids, 2014, 28, 2395-2405.	1.0	31
51	Immediate antiretroviral therapy in young HIV-infected children. Current Opinion in HIV and AIDS, 2014, 9, 87-94.	1.5	16
52	Mortality in perinatally <scp>HIV</scp> â€infected young people in <scp>E</scp> ngland following transition to adult care: an <scp>HIV Y</scp> oung <scp>P</scp> ersons <scp>N</scp> etwork (<scp>HYPNet</scp>) audit. HIV Medicine, 2014, 15, 239-244.	1.0	85
53	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	2.9	140
54	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Medicine, 2013, 10, e1001510.	3.9	256

#	Article	IF	CITATIONS
55	Predictors of CD4+ T-Cell Counts of HIV Type 1–Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	1.9	7
56	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/µL in the Post–Combination Antiretroviral Therapy Era. Clinical Infectious Diseases, 2013, 57, 1038-1047.	2.9	92
57	Lopinavir Dosing in HIV-infected Children in the United Kingdom and Ireland. Pediatric Infectious Disease Journal, 2013, 32, 45-50.	1.1	27
58	Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants. Aids, 2013, 27, 991-1000.	1.0	35
59	The Prevalence of Darunavir-Associated Mutations in HIV-1-Infected Children in the Uk. Antiviral Therapy, 2012, 17, 599-603.	0.6	8
60	HIV diagnoses and missed opportunities. Results of the British HIV Association (BHIVA) National Audit 2010. Clinical Medicine, 2012, 12, 430-434.	0.8	47
61	Short- and Long-term Immunological and Virological Outcome in HIV-Infected Infants According to the Age at Antiretroviral Treatment Initiation. Clinical Infectious Diseases, 2012, 54, 878-881.	2.9	26
62	Recent advances in pharmacovigilance of antiretroviral therapy in HIV-infected and exposed children. Current Opinion in HIV and AIDS, 2012, 7, 305-316.	1.5	9
63	The Prevalence of Darunavir-Associated Mutations in HIV-1-Infected Children in the Uk. Antiviral Therapy, 2012, 17, 599-603.	0.6	0
64	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infectious Diseases, The, 2012, 12, 119-127.	4.6	41
65	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 294-299.	0.9	13
66	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infectious Diseases, The, 2011, 11, 363-371.	4.6	345
67	Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet, The, 2011, 377, 1580-1587.	6.3	101
68	Early antiretroviral therapy in HIV-1-infected infants, 1996–2008. Aids, 2011, 25, 2279-2287.	1.0	37
69	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. Archives of Internal Medicine, 2010, 170, 410-419.	4.3	42
70	Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case–control study. Aids, 2010, 24, 525-534.	1.0	39
71	Young People in the United Kingdom and Ireland with Perinatally Acquired HIV: The Pediatric Legacy For Adult Services. AIDS Patient Care and STDs, 2009, 23, 159-166.	1.1	76
72	Improving survey methods in sero-epidemiological studies of injecting drug users: a case example of two cross sectional surveys in Serbia and Montenegro. BMC Infectious Diseases, 2009, 9, 14.	1.3	15

#	Article	IF	CITATIONS
73	Vertically acquired HIV diagnosed in adolescence and early adulthood in the United Kingdom and Ireland: findings from national surveillance. HIV Medicine, 2009, 10, 253-256.	1.0	26
74	Tenofovir Use in Human Immunodeficiency Virus-1–Infected Children in the United Kingdom and Ireland. Pediatric Infectious Disease Journal, 2009, 28, 204-209.	1.1	40
75	Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. Aids, 2009, 23, 597-604.	1.0	82
76	Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study. Antiviral Therapy, 2009, 14, 1065-1074.	0.6	92
77	Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. Journal of Viral Hepatitis, 2008, 15, 250-254.	1.0	102
78	HIV-1 DRUG RESISTANCE IN HIV-1-INFECTED CHILDREN IN THE UNITED KINGDOM FROM 1998 TO 2004. Pediatric Infectious Disease Journal, 2008, 27, 457-459.	1.1	29
79	Response to combination antiretroviral therapy: variation by age. Aids, 2008, 22, 1463-1473.	1.0	188
80	Differences in Factors Associated With Initial Growth, CD4, and Viral Load Responses to ART in HIV-Infected Children in Kampala, Uganda, and the United Kingdom/Ireland. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 384-392.	0.9	65
81	Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. International Journal of Epidemiology, 2007, 36, 396-405.	0.9	79
82	Effects of Sex Work on the Prevalence of Syphilis Among Injection Drug Users in 3 Russian Cities. American Journal of Public Health, 2007, 97, 478-485.	1.5	45
83	Morbidity, Mortality, and Response to Treatment by Children in the United Kingdom and Ireland with Perinatally Acquired HIV Infection during 1996-2006: Planning for Teenage and Adult Care. Clinical Infectious Diseases, 2007, 45, 918-924.	2.9	194
84	Twenty years of selective hepatitis B vaccination: is hepatitis B declining among injecting drug users in England and Wales?. Journal of Viral Hepatitis, 2007, 14, 584-591.	1.0	21
85	Hepatitis B vaccine uptake among injecting drug users in England 1998 to 2004: is the prison vaccination programme driving recent improvements?. Journal of Viral Hepatitis, 2007, 14, 653-660.	1.0	22
86	Methods to Recruit Hard-to-Reach Groups: Comparing Two Chain Referral Sampling Methods of Recruiting Injecting Drug Users Across Nine Studies in Russia and Estonia. Journal of Urban Health, 2006, 83, 39-53.	1.8	106
87	Groin injecting in the context of crack cocaine and homelessness: From â€risk boundary' to â€acceptable risk'?. International Journal of Drug Policy, 2006, 17, 164-170.	1.6	45
88	High HIV prevalence among injecting drug users in Estonia: implications for understanding the risk environment. Aids, 2006, 20, 2120-2123.	1.0	61
89	HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years. Aids, 2005, 19, 1207-1214.	1.0	41
90	Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. Journal of Viral Hepatitis, 2005, 12, 655-662.	1.0	55

#	Article	IF	CITATIONS
91	Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia. International Journal of STD and AIDS, 2005, 16, 749-754.	0.5	36
92	Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ: British Medical Journal, 2005, 330, 24-25.	2.4	145
93	Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction, 2004, 99, 621-633.	1.7	87
94	Prevalence of personality disorder in alcohol and drug services and associated comorbidity. Addiction, 2004, 99, 1306-1314.	1.7	74
95	Injecting Equipment Sharing Among Injecting Drug Users in Togliatti City, Russian Federation. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 293-300.	0.9	44
96	Drug-Related Mortality and Fatal Overdose Risk: Pilot Cohort Study of Heroin Users Recruited From Specialist Drug Treatment Sites in London. Journal of Urban Health, 2003, 80, 274-287.	1.8	87
97	Modelling emerging HIV epidemics: the role of injecting drug use and sexual transmission in the Russian Federation, China and India. International Journal of Drug Policy, 2003, 14, 25-43.	1.6	68
98	Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. Journal of Medical Virology, 2003, 71, 49-55.	2.5	152
99	Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. Aids, 2002, 16, F25-F31.	1.0	126
100	Over a decade of syringe exchange: results from 1997 UK survey. Addiction, 2002, 97, 845-850.	1.7	30
101	Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working?. American Journal of Public Health, 2001, 91, 38-42.	1.5	68
102	Epidemiology of hepatitis C virus in injecting drug users in England and Wales: implications for HCV drug therapy. Journal of Hepatology, 2001, 34, 127.	1.8	0
103	Measuring injecting risk behaviour in the second decade of harm reduction: a survey of injecting drug users in England. Addiction, 2000, 95, 1351-1361.	1.7	44
104	Prevalence of sexual dysfunction in new heterosexual attenders at a central London genitourinary medicine clinic in 1998. Sexually Transmitted Infections, 2000, 76, 208-209.	0.8	32
105	Prevalence of Chlamydia trachomatis in young men in north west London. Sexually Transmitted Infections, 2000, 76, 273-276.	0.8	19
106	Prevalence of HIV infection in a multi-site sample of injecting drug users not in contact with treatment services in England. Aids, 2000, 14, 2413-2415.	1.0	8
107	Accuracy of perceptions of hepatitis B and C status. BMJ: British Medical Journal, 2000, 320, 512-512.	2.4	2
108	Care is required with cost effectiveness approach. BMJ: British Medical Journal, 2000, 321, 449-449.	2.4	1

#	Article	IF	CITATIONS
109	Incidence of gonorrhoea diagnosed in GUM clinics in South Thames (west) region. Sexually Transmitted Infections, 1999, 75, 306-311.	0.8	17
110	HIV prevalence and risk behaviour among female injecting drug users in London, 1990 to 1996. Aids, 1999, 13, 833-837.	1.0	10
111	IDENTIFYING ALCOHOL-RELATED HARM IN YOUNG DRINKERS: THE ROLE OF ACCIDENT AND EMERGENCY DEPARTMENTS. Alcohol and Alcoholism, 1999, 34, 910-915.	0.9	34
112	Women injecting drug users in London: the extent and nature of their contact with drug and health services. Drug and Alcohol Review, 1998, 17, 267-276.	1.1	15
113	Hyponatraemia in Premature Babies and Following Surgery in Older Children. Acta Paediatrica, International Journal of Paediatrics, 1987, 76, 385-393.	0.7	41